KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Net Cash Flow (2016 - 2025)

NovoCure (NVCR) has disclosed Net Cash Flow for 12 consecutive years, with -$241.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 949.62% to -$241.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$63.1 million through Dec 2025, up 17.3% year-over-year, with the annual reading at -$63.1 million for FY2025, 17.3% up from the prior year.
  • Net Cash Flow hit -$241.2 million in Q4 2025 for NovoCure, down from $192.5 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $330.1 million in Q3 2021 to a low of -$481.0 million in Q4 2021.
  • Historically, Net Cash Flow has averaged -$7.1 million across 5 years, with a median of $9.9 million in 2023.
  • Biggest five-year swings in Net Cash Flow: plummeted 4596.91% in 2021 and later surged 2435.48% in 2024.
  • Year by year, Net Cash Flow stood at -$481.0 million in 2021, then skyrocketed by 73.32% to -$128.4 million in 2022, then soared by 166.89% to $85.9 million in 2023, then plummeted by 126.76% to -$23.0 million in 2024, then plummeted by 949.62% to -$241.2 million in 2025.
  • Business Quant data shows Net Cash Flow for NVCR at -$241.2 million in Q4 2025, $192.5 million in Q3 2025, and $22.4 million in Q2 2025.